Objective To explore the value and operational effectiveness of establishing a donor care unit (DCU). Methods A single-center retrospective cohort study design was adopted. The DCU of the Transplant Center of the Second Affiliated Hospital of Guangxi Medical University was officially put into use on August 1, 2023. As of April 30, 2024, 200 donors were divided into the DCU group (n=107) and the non-DCU group (n=93) based on the different donor maintenance sites. Baseline data of donors, organ maintenance management indicators, organ output and utilization were collected and analyzed; simultaneously, the perioperative effects and 1-year postoperative prognosis of 314 recipients undergoing kidney transplantation at the Transplant Medicine Institute of the Second Affiliated Hospital of Guangxi Medical University were tracked. Results Compared with the non-DCU group, the usage rate of vasoactive drugs in the DCU group was lower, the completeness rate of pathogen culture and the proportion of daytime organ acquisition surgeries were higher, the cold ischemia time of the liver was shorter, the professional maintenance time of donors was longer, but the total hospitalization cost of donors was higher (all P<0.05). The 24-hour urine volume of donors in the DCU group increased, the level of creatine kinase decreased, and electrolyte indicators such as procalcitonin, lactate, blood sodium and blood chloride improved (all P<0.05). The cardiac output rate of donors in the DCU group was higher than that of the non-DCU group (P<0.05). The perioperative indicators, 1-year postoperative survival rates and graft survival rates of kidney transplant recipients in both groups were similar, but the serum creatinine level of recipients in the DCU group was lower after 1 year (P<0.05). Conclusions The management and operation efficiency of the DCU are good. By monitoring and regulating the stable physiological state of donors, the quality of organs is guaranteed, thereby improving cardiac output rate and short-term function of the transplanted kidney. The total hospitalization cost of donors is higher, and its comprehensive benefits need to be studied. However, it provides preliminary evidence-based basis for the clinical application of the DCU.

[ABSTRACT]OBJECTIVETo investigate the therapeutic effect of early combination treatment with intratympanic glucocorticoid injection for sudden sensorineural hearing loss(SSNHL).METHODSTotal of 178 patients with diagnosis of SSNHL, including 44 with hearing loss at middle-low frequencies,50 at high frequencies,44 at all frequencies and 40 at total deafness, were randomly divided into combination treatment group (CT group) and systemic oral prednisone group (OP group).CT group (82 patients) received intratympanic administration of methylprednisolone and oral prednisone in tapering doses. Pure-tone threshold audiometry (PTA) was performed at week 8 after beginning of therapy. RESULTSIn middle-low frequencies, the final PTA and PTA improvement were 26.14±24.82 dB and 42.23±1.61 dB in CT group respectively, and were 37.91±13.98 dB and 30.00±13.30 dB in OP group respectively (both P<0.05). In high frequencies, all frequencies and total deafness SSNHL group, the differences of the final PTA and PTA improvement were not statistically significant in both groups. The PTA improvement in CT group for total deafness (26.52±14.03) dB was more than that of OP group (22.06±11.17)dB (t=2.361,P<0.05). In middle-low frequencies, the recovery rate was 72.73%(16 cases) in CT group, and 40.91% (9 cases) in OP group, the difference was significant (χ2=4.539,P<0.05), but not in apparent effective rate, effective rate and total effective rate. In high frequencies, all frequencies and total deafness, there were no significant differences in therapeutic effect. The recovery rate of total CT group (40.24%) was significantly increased compared with that of OP group (26.04%)(χ2=4.061,P<0.05), the differences of apparent effective rate, effective rate and total effective rate were not statistically significant in both groups.CONCLUSIONFor low-middle frequencies SSNHL, the early combination treatment with intratympanic glucocorticoid injection leads to higher hearing recovery and therapeutic effect compared with traditional oral prednisone. Systemic application should be applied for high frequencies, all frequencies and total deafness of SSNHL.